Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Common Equity (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Common Equity for 3 consecutive years, with $110.0 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 41.08% to $110.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $110.0 million through Dec 2025, down 41.08% year-over-year, with the annual reading at $110.0 million for FY2025, 41.08% down from the prior year.
  • Common Equity for Q4 2025 was $110.0 million at Artiva Biotherapeutics, down from $129.2 million in the prior quarter.
  • The five-year high for Common Equity was $201.0 million in Q3 2024, with the low at -$191.1 million in Q2 2024.
  • Average Common Equity over 3 years is $9.2 million, with a median of $110.0 million recorded in 2025.
  • The sharpest move saw Common Equity surged 232.71% in 2024, then tumbled 41.08% in 2025.
  • Over 3 years, Common Equity stood at -$162.0 million in 2023, then surged by 215.2% to $186.6 million in 2024, then crashed by 41.08% to $110.0 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $110.0 million, $129.2 million, and $149.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.